Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I
Immunotargets Ther. 2024; 13:461-486.
PMID: 39290805
PMC: 11407319.
DOI: 10.2147/ITT.S463384.
Rahhal A, Provan D, Ghanima W, Gonzalez-Lopez T, Shunnar K, Najim M
Front Med (Lausanne). 2024; 11:1348941.
PMID: 38665297
PMC: 11043582.
DOI: 10.3389/fmed.2024.1348941.
Hu R, Guo S, Liu M
Heliyon. 2024; 10(1):e24051.
PMID: 38268581
PMC: 10806291.
DOI: 10.1016/j.heliyon.2024.e24051.
Xiao Z, Murakhovskaya I
Front Immunol. 2023; 14:1215216.
PMID: 37575230
PMC: 10422042.
DOI: 10.3389/fimmu.2023.1215216.
Biolato M, Vitale F, Galasso T, Gasbarrini A, Grieco A
World J Gastrointest Surg. 2023; 15(2):127-141.
PMID: 36896308
PMC: 9988645.
DOI: 10.4240/wjgs.v15.i2.127.
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia.
Huang L, Xu J, Zhang H, Wang M, Zhang Y, Lin Q
Ther Adv Hematol. 2023; 14:20406207231152746.
PMID: 36865986
PMC: 9972067.
DOI: 10.1177/20406207231152746.
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
Ding Z, Wu H, Zeng Y, Kuang M, Yang W, Meng Z
Hepatol Int. 2022; 17(1):180-189.
PMID: 36258065
PMC: 9895009.
DOI: 10.1007/s12072-022-10421-9.
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U
World J Gastroenterol. 2022; 28(30):4061-4074.
PMID: 36157107
PMC: 9403422.
DOI: 10.3748/wjg.v28.i30.4061.
Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
Deng J, Hu H, Huang F, Huang C, Huang Q, Wang L
Front Pharmacol. 2021; 12:704093.
PMID: 34393785
PMC: 8355583.
DOI: 10.3389/fphar.2021.704093.
Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.
Audia S, Mahevas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B
Hemasphere. 2021; 5(6):e574.
PMID: 34095758
PMC: 8171374.
DOI: 10.1097/HS9.0000000000000574.
Emerging Therapies in Immune Thrombocytopenia.
Audia S, Bonnotte B
J Clin Med. 2021; 10(5).
PMID: 33801294
PMC: 7958340.
DOI: 10.3390/jcm10051004.
Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease.
Shimizu R, Katsube T, Wajima T
CPT Pharmacometrics Syst Pharmacol. 2021; 10(5):489-499.
PMID: 33797208
PMC: 8129717.
DOI: 10.1002/psp4.12623.
Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
Kaneko T, Takano Y, Ishibashi K
Medicine (Baltimore). 2021; 100(2):e24094.
PMID: 33466174
PMC: 10545426.
DOI: 10.1097/MD.0000000000024094.
Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.
Nishida Y, Kawaoka T, Imamura M, Namba M, Fujii Y, Uchikawa S
Intern Med. 2020; 60(6):829-837.
PMID: 33087674
PMC: 8024946.
DOI: 10.2169/internalmedicine.5930-20.
Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Katsube T, Inoue Y, Fukuhara T, Kano T, Wajima T
Eur J Clin Pharmacol. 2020; 76(12):1659-1665.
PMID: 32666123
PMC: 7661413.
DOI: 10.1007/s00228-020-02960-7.
Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS.
Wang B, Chen F, Zhou Q, Zhou Y, Meng D, Geng P
Int J Anal Chem. 2020; 2020:7290470.
PMID: 32550846
PMC: 7277053.
DOI: 10.1155/2020/7290470.
Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.
Poordad F, Terrault N, Alkhouri N, Tian W, Allen L, Rabinovitz M
Int J Hepatol. 2020; 2020:5421632.
PMID: 32047671
PMC: 7003278.
DOI: 10.1155/2020/5421632.
Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report.
Sasaguri T, Hirakawa N, Uemura S
JA Clin Rep. 2020; 4(1):80.
PMID: 32025904
PMC: 6966968.
DOI: 10.1186/s40981-018-0217-7.
Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists.
Nilles K, Caldwell S, Flamm S
Hepatol Commun. 2019; 3(11):1423-1434.
PMID: 31701067
PMC: 6824078.
DOI: 10.1002/hep4.1423.
Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
Cheloff A, Al-Samkari H
J Blood Med. 2019; 10:313-321.
PMID: 31565009
PMC: 6733339.
DOI: 10.2147/JBM.S191790.